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BACKGROUNDː Treatment of patients with chronic venous disease (CVD) may be 
influenced by national reimbursement systems. In Belgium, catheters or fibers used for 
endovenous thermal ablation (EVTA) are reimbursed only once in a lifetime. The potential 
impact of the Belgian public health insurance reimbursement policy on surgical practice in 
phlebology needs to be investigated. 
 
METHODSː Billing data available from the Belgian National Institute for Health and 
Disability Insurance (NIHDI) were used for analysing the distribution of specific surgical 
procedures for treating varicose veins and their relative use from 2007 to 2017. The potential 
influence of age, sex, social status and geographical origin of insured patients on surgical 
practice in Belgium were studied. 
 
RESULTSː The annual intervention rate was 343 per 100,000 insured individuals for 2017 with 
a slight annual increase over the period 2007-2017 (+ 0.83% per year). Patients with limited 
resources, benefiting from a preferential reimbursement system, had a significantly lower 
intervention rate than those having the usual system (p<0.001). There was a large geographica l 
variation in the use of care, ranging from 172 to 549 per 100.000 insured in 2017. The number 
of classic surgical procedures decreased (-6.17% per year) in the period 2015-2017) while 
EVTA, newly reimbursed in Belgium since 2012, increased during the same period (+ 3.6% 
per year). This evolution was more pronounced in the north (Flanders) than in the south 
(Wallonia) of the country. Bilateral treatment increased considerably from 2012 and stabilized 
at 33% of all surgical interventions in 2016 and 2017. 
 
CONCLUSIONSː Available data of the NIHDI in Belgium highlight remarkable differences in 
the use of care for CVD, depending on social status and geographical origin of insured patients. 
The introduction of EVTA techniques has been adopted more rapidly in the north of the country 








The prevalence of Chronic Venous Disease (CVD) is high, with a multifactorial etiology.1 The 
risk factors for its occurrence are age and gender, family history and pregnancies.2 A sedentary 
lifestyle and being overweight aggravate the symptoms.3 The diagnosis is essentially clinica l 
(the ‘C’ of the CEAP classification, Clinical Etiological Anatomical Pathophysiologica l 
classification)4 but it should be systematically supplemented by a duplex ultrasound to clarify 
the anatomy, etiology and pathophysiology, to determine the treatment strategy. The goal of 
treatment is to reduce the venous hypertension that causes CVD. The variability of clinica l 
presentations accounts for the diverse range of treatments that are offered worldwide. Apart 
from a conservative approach by means of compression, physical exercise and venotonic 
medication, there are also a number of potential interventions available, which may be chemica l 
(sclerotherapy), thermal (laser, radiofrequency ablation) or surgical (high ligation, stripping and 
phlebectomy).5   These treatments may be used as single treatments or may be combined. New 
techniques have emerged in recent decades and have proven their efficacy with a higher level 
of safety and have dramatically changed the management of CVD.6 At present, internationa l 
guidelines recommend endovenous treatments as a first choice for patients with varicose veins 
and more advanced CVD.7-8  
Treatment of patients with CVD may be influenced by national reimbursement systems. In 
Belgium, endovenous thermal ablation (EVTA), mainly laser and radiofrequency ablation, has 
been reimbursed since 2012.9-10 However, there is an important restriction in reimbursement: 
catheters or fibers used for EVTA are reimbursed only once in a lifetime. 
In Belgium 99% of the population has access to health care reimbursement11, hence the billing 
data available from the Belgian National Institute for Health and Disability Insurance 
(NIHDI)12 make it possible to analyze the intervention rates and their relative proportion related 
to age, gender or social status, in a specific field of medicine, for instance varicose veins and 
CVD. It is also possible to know the type of intervention carried out, their geographica l 
distribution over the country, their evolution over time and the influence of changes in 
reimbursement policies. The NIHDI has started publishing public standard reports on variations 
in practice since April 2019.12-13 This material opens up an opportunity to medical associations, 
like the Phlebology Working Group of the Belgian Society of Vascular Surgery, to look at their 
own practice, trying to understand the distribution and evolution of phlebological surgica l 
practice in Belgium over the last 10 years (2007-2017). 
The aim of the present study was therefore to better understand phlebological practice in 
Belgium by addressing several questions. Are Belgian data consistent with internationa l 
epidemiological data? What can we learn about surgical practice in phlebology in Belgium? 
Did this practice evolve in line with international recommendations? Is it possible to identif y 
factors influencing the evolution of Belgian phlebological practice? Finally, as endovenous 
techniques have been reimbursed in Belgium since the end of 2012,9-10 to what extent has 
reimbursement policy influenced the establishment of these techniques in Belgium? 
 
Materials and methods 
 
Billing (reimbursement) codes of specific phlebological surgical procedures in Belgium were 
selected for this study.14 Interventions consisting of sclerotherapy only were excluded. There 
are 10 surgical reimbursement codes and two codes for reimbursement of equipment (Table I). 
Three codes are certified for phlebectomy invoicing, one code for small saphenous vein (SSV) 
ablation, five codes for great saphenous vein (GSV) ablation, one code for bilateral varicose 
veins ablation and another one for surgical ligation of perforating veins. There are no specific 
codes for endovenous techniques available so far. Therefore, to calculate the number of thermal 
ablations performed, we additionally queried the billing codes related to reimbursement of 
specific equipment used for these endovenous techniques. We should also note that the present 
analysis is based on the hypothesis that only one of the selected codes is invoiced to the same 
patient on the same day, because the reimbursement rules stipulate a priori that they cannot be 
cumulated. 
The research addressed a variety of techniques for varicose veins and their rate of use based on 
age, gender, social security status and geographical origin during the period 2007-2017. 
Belgium can be subdivided into 43 districts and globally into 3 main regions (Flanders, 
Wallonia and Brussels). The results comparing regions were standardized by age group, gender, 
and social security status.12 The social security status of insured persons indicates whether they 
have a low income and are eligible for an enhanced reimbursement of health care (preferentia l 
system) or they have a normal reimbursement system. In 2016, 18.9% of the insured were 






The data presented in this document are based on the entire population. Therefore, descriptive 
statistics (mean, median), were used to illustrate the techniques applied for treatment of varicose 
veins in Belgium.  
Whenever descriptive statistics highlighted potentially interesting differences between regions, 
techniques and periods, hypotheses derived from these observations were tested by performing 
several statistical analyses on the data. In general, analyses with a variable of geographica l 
location were performed on standardized data.12 While the data for the entire population could 
be analysed, data per insured was not available. Therefore, the rate of use of care was computed 
per district, as well as per age category, gender and reimbursement type, and used for statistica l 
testing. To investigate whether or not there was a trend break between the period 2007-2017 
and 2015-2017 (overall and by region), regression coefficients were compared using a t-test 
that takes into account the standard error of each regression coefficient and the number of years 
used in the regression. Additionally, to investigate whether the geographical distribution 
differed between the beginning and end point of the measurements, the coefficients of variation 
(i.e. the ratios of the standard deviation to the mean, expressed as a percentage, to measure 
relative variability) from 2007-2009 and 2015-2017 were compared using Chi-Squared test for 
an asymptotic distribution.16 These analyses were conducted based on the overall rate of 
interventions and for each technique used separately. 
Secondly, to investigate whether technique, region, gender or preference scheme significantly 
influenced differences in utilization rate in 2017, a 4-way ANOVA with technique (3 levels : 
phlebectomy, perforating veins surgery, high ligation and stripping), region (3 levels: Brussels, 
Flanders, Wallonia), gender (2 levels) and reimbursement system (2 levels) was used. For this 
analysis the raw data (not standardized) were studied. Testing effects were based on the type 
III sum of squares as the data were unbalanced and the reported p-values were corrected for 
multiple testing using the Tukey-Kramer method.  
Finally, to further investigate uni- and bilateral interventions another 4-way ANOVA was used 
with type intervention (2 levels: uni- and bilateral), region, gender and reimbursement system. 
All statistical analysis were performed using SAS/EG 9.4 and Excel 2016 (Microsoft Office 
Professional Plus 2016). 





Overall intervention rates  
The main results of the study are summarised in Table II. For classic surgery (high ligat ion 
and stripping), EVTA, perforating vein surgery and phlebectomy the annual mean 
intervention rate was 343 per 100,000 insured individuals for 2017, giving 37,333 
interventions per year (for a total population of 11.000.000 inhabitants). Not taking into 
account phlebectomies and other interventions for small varicose tributaries, the rate falls to 
229 per 100,000 insured. The average expenses for varicose veins surgery exceeded 10 
million euro per year. The vast majority of the interventions were carried out by surgeons 
(99%).  
The mean age of the patients was 53.4 year (SD=13.8). Seventy percent of the interventions 
were carried out within the range of 40 to 69 years, regardless of gender. 
For 2017, 74.6% of these procedures were done for women (p<0.001). This female 
predominance was observed for all age groups. This difference did not vary according to 
geographical region. 
Most varicose vein surgery was performed on an outpatient basis (mainly day surgery) (91.5%). 
However, there were marked regional differences with a lower rate of one day hospitalizat ion 
in Brussels and Wallonia (87%) and 94% in Flanders. Day hospitalization has been progressing 
for 10 years, having increased from 79 to 91% on average. 
The global rate of use of care was 364 per 100,000 insured persons for those under the regular 
reimbursement system whereas it was 250 per 100,000 for insured persons with PS (p<0.001) 
(Fig 1). Additionally, there was a significant two-way interaction for gender and reimbursement 
type (PS) (p< 0.001). Comparisons showed that there was a significant lower average rate of 
use of care between reimbursement system for women (p < 0.001) but not for men (p = 0.46). 
The two-way interaction for region and gender and region and reimbursement type was not 
significant (both p ≥ 0.05). 
During the period from 2007 to 2017, we observed a slight increase in the rate of interventions 
(+ 0.83% per year). During the period, 2015 to 2017, however, the number of interventions 
diminished by 3.86% per year with no differences between regions (Fig 2). This difference in 
trends between periods was statistically significant (p<0.01). 
Large geographical disparities were observed in the use of care: in 2017, it ranged from 172 to 
549 per 100.000 insured in the different districts (Fig 3). Interestingly, the coefficient of 
variation (39%, over the period 2007-2009) decreased significantly in more recent years (19%, 
for the years 2015-2017) (p<0.001) (Table II). 
 
Variations according to techniques 
Of all the surgical interventions for CVD, 62% concerned surgical interventions on saphenous 
trunks, by stripping or endovenous techniques. Phlebectomies also represented one third of the 
procedures (33%), while perforator ligation was declared in 5% of cases. The proportion of 
minimally invasive, laser or radiofrequency interventions, counted for 53% of interventions on 
the saphenous trunks, representing 33% of all interventions.  
Trends in utilization rates were quite different from one technique to another (Table II).  
There was a significant decrease in high ligation/stripping as well as in perforator ligation in 
2015-2017 compared to the whole decade (for both p<0.001). On the other hand, there was a 
significant increase in the use of phlebectomies (p<0.01). The use of EVTA techniques, which 
were not reimbursed before 2012, was increasing fast with a rate of 3.6% per year during 2015-
2017.  
Variations in techniques showed great disparities between regions: based on the intervention 
rate for 2017 the four-way ANOVA showed a significant main effect for region, (p = 0.03). 
The average rate of use for high ligation and stripping was significantly higher in Wallonia than 
in in Flanders (p < 0.001), whereas the rate of EVTA was lower in Wallonia than in Flanders 
(p<0.001). The average phlebectomy rate was significantly larger in Flanders than in Wallonia 
(p< 0.001). 
 
Unilateral versus bilateral interventions on saphenous trunks 
A total of 7.854 bilateral interventions were carried out in 2017, representing 34% of all 
saphenectomy interventions, regardless of the technique used (endovenous or surgical). These 
procedures are performed less frequently in an ambulatory setting (only in 85%).  
Examining possible trends in the last decade, we found a slight divergence between unilatera l 
and bilateral interventions. Unilateral interventions were stable in the last decade (+0.24% / 
year) but decreased sharply in the last period (-13.18%/ year 2015-2017). The bilateral ones, 
which had been growing since 2007 (+6% per year), were decreasing slightly since 2015 (-
1.46%) especially in Wallonia (-4.78 % over 2015-2017). As a result, the percentage of bilatera l 
procedures, which had been stable between 2007 and 2012 (22%), increased sharply from 2012 
onwards and then stabilized at 33% in 2016 and 2017. Figure 4 shows the evolution of the 
bilateral surgical intervention rate per 100,000 insured persons over the period 2007 to 2017 
for the entire country as well as the variations recorded by region.  
Based on the rate of use of interventions on saphenous trunks for 2017 the four-way ANOVA 
showed a significant main effect for the type of intervention (uni- versus bilateral), (p < 0.001). 
The average rate of use of unilateral interventions was still significantly higher than that of 
bilateral interventions (p< 0.001). 
There was also a significant effect for region, (p < 0.001). Comparisons indicated that there was 
a significant difference in average rate of use of bilateral procedures between Flanders and 
Wallonia (p<0.001) and between Flanders and Brussels (p= 0.001) (Fig 4). The average rate in 




This study analysed the variation in utilization of several surgical techniques for treating 
varicose veins in Belgium, based on registered billing information. We looked at the global use 
of care and the influence of patient-related variations, such as age, gender, social status (based 
on the reimbursement system covering individual patients) and geographical origin. Globally, 
there was a large female preponderance, the underprivileged social classes used less care than 
expected and there was a remarkably large geographical disparity in care.  Differences in the 
use of certain techniques like phlebectomies and the use of endovenous procedures were mainly 
based on geographical location, being more frequently used in Flanders than in Wallonia.  
 
Global use of care for varicose veins 
In 2017, 343 patients per 100,000 insured underwent a treatment for varicose veins (C2-C6). 
This may seem quite high, if compared to data from the international literature, where such 
numbers are usually rather cited for more severe cases of CVD (C3-C6).17-20 It should be 
pointed out, however, that intervention rate falls to only 229 per 100,000 if interventions for 
varicose tributaries are not included.  
A decreasing rate of interventions has been observed starting in 2015. The same evolution has 
also been described in other European countries.21 The diminishing number of interventions 
cannot be accounted for by an epidemiologic change. The underlying hypothesis is that the 
reduction seen is associated with the increased application of techniques which cannot be 
detected by looking at the existing codes for surgery: for instance, it is most likely that 
ultrasound-guided foam sclerotherapy (UGFS), not included in the coding system yet, is 
gradually replacing surgical techniques for treating refluxing saphenous trunks in certain 
indications, conform international guidelines.7-8 
Despite recent stabilization of the use of care after an unexplained period of sustained growth 
between 2009 and 2011, the rate of use has remained particularly high in Flanders in 
comparison with both Wallonia and Brussels (Fig 2). One of the reasons may be that in 
Flanders the use of endovenous interventions is more established, than in the two other regions. 
Since the side-effects, especially pain after the procedure, are less pronounced after endovenous 
treatment, the threshold to be treated may be lower for patients in Flanders. 
 
Patient related variations 
Women are over-represented in the use of care for varicose veins, since they account for about 
three-quarters of interventions. This is even more pronounced for phlebectomy, where the rate 
rises to 85%. These figures are seen in every region in Belgium and for the different types of 
insured persons. Epidemiological studies show that venous disease is more common among 
women than men.22
 
In Belgium the female/male ratio is at the upper end of the range seen 
internationally, where the ratio tends to be more about 2 to 1. This raises the question of relative 
underuse of care by men, or relative overuse by women.
 
 
The median age at which patients undergo operations for varicose veins is 54 years, both for 
men and for women, for all techniques and across all regions. This result was expected in view 
of the natural history of CVD, which becomes worse with age, balanced against surgical risks.23-
28  
A third type of variability in practice is quite remarkable: patients belonging to the most 
underprivileged social classes, covered by the PS, are clearly under-represented in all the 
categories studied. Access to care, including surgery, endovenous techniques and phlebectomy 
is almost 50% lower in this group. These differences are surprising in comparison with other 
studies on variability in practice in Belgium, where social status did not seem to influence the 
use of care.
12 
Moreover, the difference is significant only for women. It is therefore difficult to 
link this lower rate to difficulties in access to care only. An explanation would be that, among 
these social classes, treatment for CVD is rather considered as an unnecessary luxury. This 
difference in use of care is regrettable since late treatment, at more severe stages of CVD, entails 
more risks of deterioration in socio-professional and quality of life terms and also has adverse 
economic consequences.29 
Finally, major geographical disparities are seen in the use of care for varicose veins. This 
variability appears to reveal large differences between treatment practice over the country. 
Obviously, these cannot be accounted for by epidemiology of CVD or by internationa l 
recommendations. It is difficult to conclude whether these regional differences are rather linked 
to specific surgical practices30 or to patients’ habits. 
 
Choice of surgical procedure 
Four types of surgical interventions were included: high ligation and stripping, endovenous 
techniques, phlebectomy and surgical ligation of perforating veins. The first three account for 
approximately equal shares. Ligation of perforating veins, which accounts for only 5% of 
interventions, is only carried out in certain regions. Variability in practice appears to be mostly 
geographical rather than being linked to patient characteristics.  
The high level of variability over the country in the use of phlebectomies can be questioned. Is 
it due to local surgical practice, to the replacement of this technique by UGFS or to differences 
in interpretation of the nomenclature? 
 
Replacement of stripping by endovenous techniques 
Surgical techniques to treat symptomatic saphenous incompetence have been evolving over 
recent years and international guidelines now recommend endovenous techniques as the first 
treatment choice.7-8,31-33 These minimally invasive EVTA techniques have been reimbursed in 
Belgium since the end of 2012 and are used without difference for specific age groups, gender 
or type of reimbursement system (usual or PS). The observed variability is essentially related 
to the patient's geographical location: the implementation of endovenous techniques does not 
seem to be as rapid in Wallonia as in Flanders. It can be hypothesized that this will change over 
time, as these techniques become more established, also in the south of the country. 
Along with the introduction of endovenous techniques, there has been a significant increase in 
bilateral interventions, from 22% in 2007, which corresponds to general epidemiological data, 
to 33% in 2017. This increase was significantly more striking in Flanders than in Wallonia. The 
fact that endovenous equipment is eligible for reimbursement only once in a patient's lifet ime 
in Belgium carries a risk of encouraging over-treatment, by excessive scheduling of bilatera l 
interventions from the outset, also in cases where only a unilateral treatment may have been 
needed.  Offering treatment of the contralateral leg without proper indication is not supported 
by any international guideline.  
 
Limitations of the study  
Several possible biases and limitations should be highlighted, mainly directly linked to the 
Belgian coding and billing system.  
First, sclerotherapy could not be analyzed in the present study. Indeed, there is only one 
reimbursement code for sclerotherapy, which covers the various indications and techniques 
used, from micro-sclerotherapy for minor telangiectasia and reticular veins (C1) up to UGFS 
of saphenous trunks. It is not possible to differentiate between indications for treatment 
(clinical and duplex ultrasound findings) based on the billing codes. Hence, we were not able 
to measure the use of UGFS, although this is nowadays an essential technique in the 
management of CVD. Invoicing practices probably vary from one clinician to another, and a 
code for sclerotherapy may be linked to a duplex ultrasound or even to a phlebectomy code. 
This, of course, is a wrong interpretation of the reimbursement rules, due to the absence of a 
proper coding for reimbursement of UGFS and makes a proper evaluation of the impact of 
UGFS in Belgium impossible.  
Second, the rate of use for endovenous interventions may have been underestimated, related to 
the fact that reimbursement of EVTA techniques is only allowed to be certified once in a 
patient’s lifetime. If a patient needs to undergo a second operation using again an endovenous 
technique, the healthcare institution has to provide the catheter or fiber and equipment without 
any reimbursement and the intervention is usually coded as ‘classic’ surgery. Hence in the 
present study such cases were erroneously added to the wrong category of treatment technique. 
We estimate, however, that the impact of such errors is not very significant, since 
reimbursement for the equipment in Belgium only began recently and hence not so many 
patients will have undergone a second intervention already since the end of 2012.  
Third, endovenous treatment of the small saphenous vein only is not eligible for reimbursement, 
unless the small saphenous vein is treated at the same time as the great saphenous vein. It is 
unknown if and how surgeons certify these interventions. 
Fourth, the rate of use can be influenced by the number of procedures by patient during the 
same year (more procedures the same day, or more procedures during the same year). We have 
not studied whether there have been one or more interventions for a single patient in a single 
year, which may have slightly influenced the results.  
Finally, the rate of use can be influenced by the surgeons’ habits or his/her workplace. In this 
study the geographical criteria are linked to the patient's geographical origin and not the 
geographical location of the place of treatment. However, it is likely, but not certain, that most 
patients choose a health care institution close to their home for treatment of CVD. 
 
Conclusion 
In 2017, 343 patients per 100,000 insured underwent a treatment for varicose veins in 
Belgium, representing a stable situation over the last 10 years. Although there is access to 
health care for all inhabitants, there is a strikingly lower use of care for varicose veins by 
individuals with a low income. Endovenous techniques have been implemented at a faster 
pace in the north than in the south of the country. There are remarkably more bilateral 
varicose veins procedures than in surrounding countries. The wide geographical variations in 
treatment techniques may depend more on the surgeon’s habits or patients’ expectations than 
on international scientific guidelines. 
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allons-nous ? Impact des nouvelles technologies sur les pratiques médicales. Phlébologie 
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Table 1.: Reimbursement codes of venous surgery in Belgium 
 
Codification                  
 
 
1619190-161921        all equipment used for complete single or bilateral  
                                       endovenous treatment of varicose veins of the lower  
                                       limbs with laser or radiofrequency during the treatment 
                                        238173-238184, 238210-238221, 238276-238280  
                                       of the classification of the billing codes (nomenclature) (since 2014) 
 
688996- 689500          all equipment used for complete single or bilateral                  
                                       endovenous treatment of varicose veins of the lower  
                                       limbs with laser or radiofrequency during the treatment  
                                       238173-238184, 238210-238221, 238276-238280  
                                       of the classification of the billing codes (nomenclature) (2012-2014) 
 
238070-238081           ligation, fulguration or resection: one varicose vein 
 
238092-238103           ligation, fulguration or resection: two or three varicose veins 
 
238114-238125           ligation, fulguration or resection of more than three varicose veins 
 
238136-238140           total removal of the small saphenous vein 
 
238151-238162           high ligation of the great saphenous vein          
 
238195-238206           high ligation and total resection of one of the two saphenous veins 
 
238210-238221           high ligation and stripping of the great and small saphenous vein  
 
238232-238243           high ligation and ligation, fulguration or resection of varicose veins 
                                        
 
238276-238280            bilateral resection of the great or small saphenous vein         
 
238291-238302            total sub-aponeurotic ligation of the perforating veins of a lower limb 
 





Table II.: Summary of main study results 
 
see appendix 1 
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Figure 1     
Comparison of intervention rate for chronic venous disease according to social security 
status by region (2017) 
H.C. services: health care services (for varicose veins and more advanced chronic venous 
disease); TOTAL: the whole country Belgium; normal system: patients benefiting from the 
usual reimbursement; preferential system: patients with a low income, benefiting from 
enhanced reimbursement of health care services 
 
Figure 2 
Evolution of intervention rate for chronic venous disease by region (2007 – 2017) 
H.C. services: health care services (for varicose veins and more advanced chronic venous 
disease); TOTAL: the whole country Belgium 
 
Figure 3 
Geographical variations in surgical interventions for chronic venous disease in Belgian 
districts (2017). The color scale indicates the coefficient of variation, which is expressed as a 
percentage: orange and red colors indicate districts with more use of care for chronic venous 
disease than the mean for Belgium, green colors those with less. 11  
 
Fig 4 
Evolution of bilateral interventions rate for chronic venous disease by region (2007-
2017) 
H.C. services: health care services (for varicose veins and more advanced chronic venous 
disease); Total: the whole country Belgium 
 
 
